BioTuesdays

Tag - NXTC

NextCure
Markets

BTIG slashes NextCure PT to $27 from $61

BTIG more than halved the price target for NextCure (NASDAQ:NXTC) to $27 from $61 after the company announced that its NC318 immunoncology antibody would not be moving forward into stage 2 of the Simon-2-stage trial in...

July 14, 2020
NextCure
Markets

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

November 26, 2019